Even with aggressive surgical treatment, relapse rates remain high for patients with resectable non–small-cell lung cancer (NSCLC). In an effort to improve survival in these patients, numerous clinical trials have evaluated neoadjuvant and adjuvant chemotherapy.
Methods:
The authors reviewed the results of the prospective randomized clinical trials that have established adjuvant chemotherapy as the standard of care for patients with surgically resected NSCLC. In addition, the authors summarize data on predictive and prognostic markers for patients with early-stage NSCLC and discuss novel therapies and clinical trials currently underway in early-stage NSCLC.
Results:
Three large randomized clinical trials and two meta-analyses have demonstrated a survival benefit for adjuvant cisplatin-based chemotherapy compared with surgery alone in patients with early-stage NSCLC. As a result, adjuvant cisplatin-based chemotherapy is recommended as the standard of care in these patients. Numerous promising biomarkers and agents have been developed in the metastatic setting and are currently being evaluated in the adjuvant setting.
Conclusions:
While adjuvant chemotherapy has improved survival for patients with early-stage NSCLC, the prognosis for early-stage lung cancer remains poor. Incorporation of molecular markers and targeted therapies into the management of patients with advanced NSCLC has improved outcomes. Development of these strategies in the adjuvant setting offers the potential to increase cure rates in patients with early-stage NSCLC.
References
1.
ParkinD.M., BrayF., FerlayJ.. Global cancer statistics, 2002.CA Cancer J Clin.2005; 55(2): 74–108.
2.
RasoM., WistubaI.. Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkersJ Thorac Oncol.2007; 2(7): S128–S135.
3.
RuckdeschelJ., SchwartzA., BeplerG.. Cancer of the lung: NSCLC and SCLC. In: AbeloffM., ArmitageJ., NiderhuberJ.. eds. Clinical Oncology.Philadelphia, PA: Elsevier;2004: 1649–1743.
4.
ChanskyK., SculierJ., CrowleyJ.. The International Association for the Study of Lung Cancer Staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.J Thorac Oncol.2009; 4(7): 792–801.
Non-Small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials.BMJ.1995; 311(7010): 899–909.
7.
KellerS.M., AdakS., WagnerH.. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer.N Engl J Med.2000; 343(17): 1217–1222.
8.
ScagliottiG.V., FossatiR., TorriV.. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer.J Natl Cancer Inst.2003; 95(19): 1453–1461.
9.
DouillardJ-Y, RosellR., De LenaM.. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.Lancet Oncol.2006; 7(9): 719–727.
10.
WintonT., LivingstonR., JohnsonD.. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.N Engl J Med.2005; 352(25): 2589–2597.
11.
Le ChevalierT., DunantA., ArriagadaR.. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC) (abstract 7507).J Clin Oncol.2008; 26 (15S): 398s.
12.
WallerD., PeakeM.D., StephensR.J.. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.Eur J Cardiothorac Surg.2004; 26(1): 173–182.
13.
ArriagadaR., BergmanB., DunantA.. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.N Engl J Med.2004; 350(4): 351–360.
14.
VincentM.D., ButtsC., SeymourL.. Updated survival analysis of JBR.10: a randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC).J Clin Oncol.2009; 27 (15S): 7501.
15.
StraussG.M., HerndonJ.E.II, MaddausM.A.. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups.J Clin Oncol.2008; 26(31): 5043–5051.
16.
PignonJ-P, TribodetH., ScagliottiG.V.. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group.J Clin Oncol.2008; 26(21): 3552–3559.
17.
DautzenbergB., BenichouJ., AllardP.. Failure of the perioperative PCV neoadjuant polychemotherapy in resectable bronchogenic non-small cell lung cancer.Cancer.1990; 65(11): 2435–2441.
18.
RothJ.A., FossellaF., KomakiR.. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer.J Natl Cancer Inst.1994; 86(9): 673–680.
19.
RosellR., Gomez-CodinaJ., CampsC.. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.N Engl J Med.1994; 330(3): 153–158.
20.
RothJ.A., AtkinsonE.N., FossellaF.. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.Lung Cancer.1998; 21(1): 1–6.
21.
BurdettS., StewartL., RydzewskaL.. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer.J Thorac Oncol.2006; 1(7): 611–621.
22.
DePierreA., MilleronB., Moro-SibilotD.. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer.J Clin Oncol.2002; 20(1): 247–253.
23.
PistersK., VallieresE., BunnP.. S9900: A phase III trial of surgery alone or surgery plus pre-operative (pre-op) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results.J Clin Oncol.2006; 24: 7012.
GilliganD., NicolsonM., SmithI.. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.Lancet.2007; 369(9577): 1929–1937.
26.
OlaussenK.A., DunantA., FouretP.. DNA Repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med.2006; 355(10): 983–991.
CoboM., IslaD., MassutiB.. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small cell lung cancer.J Clin Oncol.2007; 25(19): 2747–2754.
29.
BeplerG., GautamA., McIntyreL.M.. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small cell lung cancer.J Clin Oncol.2002; 20(5): 1353–1360.
30.
ZhengZ., ChenT., LiX.. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.N Engl J Med.2007; 356(8): 800–808.
31.
MikiY., SwensenJ., Shattuck-EidensD.. A strong candidate for the breast and ovarian cancer susceptability gene BRCA1.Science.1994; 266(582): 66–71.
32.
RosellR., SkrzypskiM., JassemE.. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.PLoS One.2007; 2(11): e1129.
33.
TaronM., RosellR., FelipE.. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.Hum Mol Genet.2004; 13(20): 2443–2449.
34.
CoboM., MassutiB., MoránT.. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels.J Clin Oncol.2008; 26 (15S): 7533.
35.
McLeodH.L., CassidyJ., PowrieR.H.. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.Clin Cancer Res.2000; 6(7): 2677–2684.
36.
HanauskeA.R., EismannU., OberschmidtO.. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.Invest New Drugs.2007; 25(5): 417–423.
37.
TakezawaK., OkamotoI., OkamotoW.. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.Br J Cancer.2011; 104(10): 1594–1601.
38.
ScagliottiG.V., ParikhP., von PawelJ.. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.J Clin Oncol.2008; 26(21): 3543–3551.
39.
WistubaI.. Molecular testing of non-small cell lung carcinoma biopsy and cytology specimens.Am Soc Clin Oncol Educ Book.2012: 459–464.
40.
MokT.S., WuY-L, ThongprasertS.. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med.2009; 361(10): 947–957.
41.
RosellR., CarcerenyE., GervaisR.. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol.2012; 13(3): 239–246.
42.
SodaM., ChoiY., EnomotoM.. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer.Nature.2007; 448: (7153) 561–566.
43.
ShawA.T., YeapB.Y., Mino-KenudsonM.. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol.2009; 27(26): 4247–4253.
44.
RodigS.J., Mino-KenudsonM., DacicS.. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res.2009; 15(16): 5216–5223.
45.
CamidgeD.R., BangY-J, KwakE.L.. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol.2012; 13(10): 1011–1019.
46.
SlebosR.J.C., KibbelaarR.E., DalesioO.. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.N Engl J Med.1990; 323(9): 561–565.
Graus-PortaD., BeerliR.R., DalyJ.M.. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.EMBO J.1997; 16(7): 1647–1655.
56.
ButtittaF., BarassiF., FresuG.. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.Int J Cancer.2006; 119(11): 2586–2591.
57.
ShigematsuH., TakahashiT., NomuraM.. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Cancer Res.2005; 65(5): 1642–1646.
LiC., SunY., FangR.. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.J Thorac Oncol.2012; 7(1): 85–89.
60.
LangerC.J., StephensonP., ThorA.. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598.J Clin Oncol.2004; 22(7): 1180–1187.
61.
GatzemeierU., GrothG., ButtsC.. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.Ann Oncol.2004; 15(1): 19–27.
62.
RossH.J., BlumenscheinG.R., AisnerJ.. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non–small cell lung cancer.Clin Cancer Res.2010; 16(6): 1938–1949.
63.
CappuzzoF., BemisL., Varella-GarciaM.. HER2 mutation and response to trastuzumab therapy in non–small-cell lung cancer.N Engl J Med.2006; 354(24): 2619–2621.
64.
De GrèveJ.L., TeugelsE., De MeyJ.. Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu.J Thorac Oncol.2009; 4 (9 suppl 1): S307.
65.
HanahanD., FolkmanJ.. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell.1996; 86(3): 353–364.
CarmelietP.. Angiogenesis in life, disease, and medicine.Nature.2005; 438(7070): 932–936.
68.
FidlerI.J., EllisL.M.. Implications of angiogenesis for the biology and therapy of cancer metastases.Cell.1994; 79(2): 185–188.
69.
WeidnerN., FolkmanJ.. Tumor vascularity as a prognostic factor in cancer. In: De VitaV.T., HellmanS., RosenbergS.A., eds. Important Advances in Oncology.Philadelphia, PA: Lippincott-Raven;1996: 167–190.
70.
PrestaL.G., ChenH., O'ConnorS.J.. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res.1997; 57(20): 4593–4599.
71.
FerraraN., HillanK.J., GerberH-P,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.Nat Rev Drug Discov.2004; 3(5): 391–400.
72.
JohnsonD.H., FehrenbacherL., NovotnyW.F.. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol.2004; 22(11): 2184–2191.
73.
SandlerA., GrayR., PerryM.C.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med.2006; 355(24): 2542–2550.
74.
NataleR.B., ThongprasertS., GrecoF.A.. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer.J Clin Oncol.2011; 29(8): 1059–1066.
75.
de BoerR.H., Arrietaó, YangC-H,. Vandetanib plus pemetrexed for the second-line treatment of advanced non–small-cell lung cancer: a randomized, double-blind phase III trial.J Clin Oncol.2011; 29(8): 1067–1074.
76.
TurnerN., GroseR.. Fibroblast growth factor signalling: from development to cancer.Nat Rev Cancer.2010; 10(2): 116–129.
77.
FischerH., TaylorN., AllerstorferS.. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.Mol Cancer Ther.2008; 7(10): 3408–3419.
78.
MarekL., WareK.E., FritzscheA.. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.Mol Pharmacol.2009; 75(1): 196–207.
79.
WeissJ., SosM.L., SeidelD.. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.Sci Trans Med.2010; 2(62): 62ra93.
80.
HammermanP.S., SosM.L., RamosA.H.. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Cancer Discov.2011; 1(1): 78–89.
81.
HoS.B., ShekelsL.L., ToribaraN.W.. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium.Cancer Res.1995; 55(12): 2681–2690.
82.
SamuelJ., BudzynskiW.A., ReddishM.A.. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.Int J Cancer.1998; 75(2): 295–302.
83.
PalmerM., ParkerJ., ModiS.. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.Clin Lung Cancer.2001; 3(1): 49–57.
84.
ButtsC., MurrayN., MaksymiukA.. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer.J Clin Oncol.2005; 23(27): 6674–6681.
85.
ButtsC., MaksymiukA., GossG.. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.J Cancer Res Clin Oncol.2011; 137(9): 1337–1342.
86.
ButtsC.A., SocinskiM.A., MitchellP.. START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.J Clin Oncol.2013; 31(suppl 18S): 7500.
87.
WuY-L, ParkK., SooR.. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.BMC Cancer.2011; 11: 430.
88.
VansteenkisteJ., ZielinskiM., LinderA.. Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of the MAGE-A3 immunotherapuetic as adjuvant therapy in stage IB/II non-small cell lung cancer.J Clin Oncol.2007; 25 (18 suppl): 7554.
89.
TyagiP., MirakhurB.. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.Clin Lung Cancer.2009; 10(5): 371–374.
90.
HodiF.S., O'DayS.J., McDermottD.F.. Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med.2010; 363(8): 711–723.
91.
LynchT.J., BondarenkoI., LuftA.. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.J Clin Oncol.2012; 30(17): 2046–2054.
92.
TopalianS.L., DrakeC.G., PardollD.M.. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity.Curr Opin Immunol.2012; 24(2): 207–212.
93.
TopalianS.L., HodiF.S., BrahmerJ.R.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med.2012; 366(26): 2443–2454.
94.
BrahmerJ.R., TykodiS.S., ChowL.Q.M.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med.2012; 366(26): 2455–2465.
